Non-destructive characterization of viscoelastic properties of hydrogels and polymers for biomedical applications

用于生物医学应用的水凝胶和聚合物粘弹性特性的无损表征

• 批准号: RTI-2017-00736
• 负责人: Lerouge, Sophie
• 金额: $ 6.2万
• 依托单位: École de technologie supérieure
• 依托单位国家: 加拿大
• 项目类别: Research Tools and Instruments
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=616755
• 关键词: Non; destructive; characterization; viscoelastic; properties

The ElastosenseBio™ (Rheolution Inc., Montreal) requested in this RTI proposal is a new technology for the characterization of viscoelastic properties of materials, especially injectable polymers and hydrogels, with and without encapsulated live cells. Thanks to its non-destructive nature and the use of sample holders, which can be removed and placed in an incubator between each analysis, the equipment allows non-invasive study of material properties over long periods of time and in the presence of encapsulated cells. It therefore opens up very interesting research opportunities in the fields of biomaterials, tissue engineering, 3D bioprinting and polymers in general. The equipment will be used in various planned and ongoing research projects at ETS, especially at Sophie Lerouge’s Canada Research Chair in biomaterials and at Nicole Demarquette’s ETS Research Chair on Blends and Nanocomposites based on Thermoplastics. Lerouge is developing and testing new injectable hydrogels as drug or cell delivery scaffolds for various applications including cancer (scaffolds for T lymphocyte delivery), tissue regeneration or blood vessel embolization. Demarquette is developing new blends based on thermosensitive polymers for use in drug delivery and nano-foams for biomedical applications derived from polymeric gels. Lerouge and Demarquette are also beginning research on bioinks for 3D printing in collaboration with other researchers from ETS and McGill, thanks to a FCI grant obtained in 2016. The equipment will be used to track mechanical properties and swelling/contraction during gelation, polymerization, biodegradation or extracellular matrix production by encapsulated cells, over short or long periods of time (several hours, days or even weeks). In contrast to existing technologies, ElastosenseBio is able to achieve this without contact (maintaining sterility) and without damaging the sample, thus allowing use of the same samples throughout the study. This is important since these samples can be very expensive. The equipment is not yet available in Canada. Acquiring the technology is urgent due to several funded projects from Lerouge which need the technology to achieve their aims, as well as the acquisition of the 3D bioprinting system in early 2017. It will also be key for industrial collaborations and HQP training. Within 3 years, we believe that the equipment will be beneficial to the work of at least 2 PDF, 4 PhD, 5 MSC and 8 interns, plus all external users.

该 RTI 提案中要求的 ElastosenseBio™（Rheolution Inc.，蒙特利尔）是一种用于表征材料粘弹性特性的新技术，特别是可注射聚合物和水凝胶，无论是否有封装的活细胞，都具有非破坏性和特性。使用样品架，可以在每次分析之间将其移除并放置在培养箱中，该设备可以在长时间内以及在存在封装的情况下对材料特性进行非侵入性研究因此，它为生物材料、组织工程、3D 生物打印和聚合物领域提供了非常有趣的研究机会。 该设备将用于 ETS 的各种计划和正在进行的研究项目，特别是 Sophie Lerouge 的加拿大生物材料研究主席和 Nicole Demarquette 的 ETS 基于热塑性塑料的共混物和纳米复合材料研究主席，Lerouge 正在开发和测试新的可注射水凝胶作为药物或药物。 Demarquette 正在开发用于各种应用的细胞输送支架，包括癌症（T 淋巴细胞输送支架）、组织再生或血管栓塞。得益于 FCI 的资助，Lerouge 和 Demarquette 也开始与 ETS 和麦吉尔的其他研究人员合作研究用于药物输送的热敏聚合物混合物以及用于生物医学应用的纳米泡沫。 2016年。 该设备将用于在短期或长期（几个小时、几天甚至几周）内跟踪封装细胞在凝胶化、聚合、生物降解或细胞外基质生产过程中的机械性能和膨胀/收缩。 ElastosenseBio 能够在不接触（保持无菌）且不损坏样品的情况下实现这一点，从而允许在整个研究过程中使用相同的样品，这一点很重要，因为这些样品可能非常昂贵。 由于 Lerouge 资助的多个项目需要该技术来实现其目标，以及 2017 年初收购的 3D 生物打印系统，因此迫切需要获得该技术。 3年内，我们相信该设备将有利于至少2名PDF、4名博士、5名MSC和8名实习生以及所有外部用户的工作。